A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells.

Area of Science:

• Immunology
• Oncology
• Biotechnology

Background:

• Chimeric antigen receptor (CAR) T-cell therapy has demonstrated success in treating hematological malignancies.
• Expanding CAR T-cell therapy to solid tumors is a critical area of research.

Purpose of the Study:

• To develop and produce potent CAR T cells targeting antigens specific to solid and liquid tumors.
• To evaluate the in vitro potency of these CAR T cells using the xCELLigence assay.
• To investigate the influence of costimulatory signaling domains, such as glucocorticoid-induced tumor necrosis factor receptor (TNFR)-related protein (GITR), on CAR T-cell efficacy.

Main Methods:

• Generation of CAR T cells via lentiviral gene transduction for preclinical studies.
• Expansion and validation of CAR T-cell expression.
• Real-time in vitro potency assessment using the impedance-based xCELLigence assay.

Main Results:

• Development of potent CAR T cells targeting tumor-specific antigens.
• Demonstration of the xCELLigence assay's utility for real-time potency evaluation.
• Insights into the impact of different costimulatory domains (e.g., GITR) on CAR T-cell function.

Conclusions:

• CAR T-cell therapy holds potential for treating solid tumors.
• The xCELLigence assay provides a sensitive method for evaluating CAR T-cell potency.
• Costimulatory signaling domains play a crucial role in optimizing CAR T-cell activity.